Chronic Myeloid Leukemia Following Liver Transplantation: A Case Report.

Ling Zhang,Bing Long,Xiao-Qing Li,Zie-Gang Fang,Wen-Xing Lai,Dong-Jun Lin
DOI: https://doi.org/10.3892/mco.2017.1465
2017-01-01
Molecular and Clinical Oncology
Abstract:Long-term utilization of immunosuppression in organ transplant recipients leads to decreased immune-mediated tumor surveillance and increased risk of developing malignant tumors. However, chronic myeloid leukemia (CML) following living donor liver transplantation (LDLT) is rarely reported. The current case report presents a 42-year-old male patient who developed CML 14 months following LDLT. The patient achieved complete hematologic remission and early molecular response at 3 months imatinib treatment and major molecular response at 12 months imatinib treatment. The pathogenesis, risk factors, treatment and prognosis for CML following liver transplantation are unclear. Therefore, further analysis through accumulation of cases will be of great importance to prevent and treat this rare complication following liver transplantation.
What problem does this paper attempt to address?